11 completed, 2 withdrawn. 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 11, Withdrawn 2 |
Follow Hydrocodone: new trials by email Literature Review of Hydrocodone trials Research Report on Hydrocodone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride - Healthy, PK Drug-drug Interaction Study | Phase 1 | Completed | Quivive Pharma, Inc. | 8 | 2025-08-18 | 2026-08-05 |
| Pain Medications Following Thyroidectomy and Parathyroidectomy Non-narcotic group regimen, Narcotic group regimen - Thyroid Disease, Parathyroid Diseases | Phase 1 | Completed | MetroHealth Medical Center | 126 | 2018-11-15 | 2019-12-26 |
| A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet - Opioid-Related Disorders, Pain, Acute | Phase 1 | Withdrawn | Grünenthal GmbH | 2017-09-01 | 2017-07-21 | |
| A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet - Opioid-Related Disorders, Pain, Acute | Phase 1 | Withdrawn | Grünenthal GmbH | 2017-09-01 | 2017-07-21 | |
| A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo - Drug Abuse | Phase 1 | Completed | Cephalon | 100 | 2012-03-01 | 2012-11-21 |
| Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment 20 mg HC-ER - Renal Impairment | Phase 1 | Completed | Zogenix, Inc. | 37 | 2011-02-01 | 2022-11-10 |
| Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment 20 mg HC-ER - Hepatic Impairment | Phase 1 | Completed | Zogenix, Inc. | 30 | 2011-02-01 | 2022-11-10 |
| A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER) HC-ER + 40% Alcohol, HC-ER + 20% Alcohol, HC-ER + 0% Alcohol - Healthy | Phase 1 | Completed | Zogenix, Inc. | 30 | 2009-11-01 | 2022-11-10 |
| Single Dose Pharmacokinetics of Egalet® Hydrocodone hydrocodone, hydrocodone & acetaminophen combination - Pain | Phase 1 | Completed | Egalet Ltd | 28 | 2008-11-01 | 2016-08-29 |
| Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate Humibid®, Hydrocodone Bitartrate, Humibid® and Hydrocodone Bitartrate tablet - Healthy Subjects | Phase 1 | Completed | Reckitt Benckiser LLC | 24 | 2007-05-05 | 2019-06-20 |
| Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension - Healthy | Phase 1 | Completed | Mallinckrodt | 43 | 2003-09-01 | 2016-10-19 |
| Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension - Healthy | Phase 1 | Completed | Mallinckrodt | 42 | 2003-09-01 | 2016-10-19 |
| To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules HC-ER 20 mg capsule (fasted), HC-ER 20 mg capsule (fed) - Healthy | Phase 1 | Completed | Zogenix, Inc. | 12 | 2002-06-01 | 2022-11-10 |
Acute Pain (2) · Opioid-Related Disorders (2) · Pain, Postoperative (2) · Pain (1) · Parathyroid Diseases (1) · Renal Insufficiency (1) · Substance-Related Disorders (1) · Thyroid Diseases (1)
Zogenix, Inc. (4) · Grünenthal GmbH (2) · Mallinckrodt (2) · Cephalon (1) · Egalet Ltd (1) · MetroHealth Medical Center (1) · Quivive Pharma, Inc. (1) · Reckitt Benckiser LLC (1)
United States (6) · Canada (2)
Herbert Neuman, MD (2) · Kenneth Lasseter, MD (2) · A. Johnston Stewart, MB, MRCGP (1) · Christine Andersen, M.Sc.Pharm (1) · Christopher R McHenry, MD (1) · Frank Lee, MD (1) · James Kissling, MD (1)